Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm
NCT03254004
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
70
Enrollment
OTHER
Sponsor class
Conditions
Lung Adenocarcinoma, Stage I
Interventions
DRUG:
Pembrolizumab
Sponsor
Samsung Medical Center